Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.39 |
| ▸ | CDK1 | P06493 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 4/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7668775 | 0.93 | PDGFRA (0.42) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7672298 | 0.92 | PDGFRA (0.39) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7666287 | 0.92 | PDGFRA (0.41) | CDK2PDGFRACCNE1CTSLNR3C1 | |
| SCHEMBL7674135 | 0.88 | PDGFRA (0.43) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7668358 | 0.86 | CCNE1 (0.39) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7661658 | 0.86 | PDGFRA (0.38) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7356565 | 0.86 | PDGFRA (0.38) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7365457 | 0.86 | PDGFRA (0.39) | CDK2PDGFRACCNE1CTSLNR3C1 | |
| SCHEMBL7670257 | 0.86 | PDGFRA (0.38) | CDK2PDGFRACCNE1CDK1CTSL | |
| SCHEMBL7661594 | 0.86 | CDK2 (0.43) | CDK2PDGFRACCNE1CDK1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | claimed |
| WO-2000037471-A1 | 2-AMINO-9-ALKYLPURINES: GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-06-29 | — | — | WO | claimed |
| US-6414147-B1 | DIAGNOSIS AND TREATMENT OF ANXIETY, DEPRESSION, SLEEP AND SEIZURE DISORDERS, DOWN'S SYNDROME, OVERDOSE WITH BENZODIAZEPINE DRUGS, AND FOR ENHANCEMENT OF MEMORY | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |